{
    "pmcid": "11361996",
    "qa_pairs": {
        "What are nanobodies derived from, according to the summary?": [
            "The variable domain of heavy chain-only antibodies found in camelids and sharks.",
            "The constant region of antibodies found in humans and mice.",
            "The light chain of antibodies found in reptiles and birds.",
            "The Fc region of antibodies found in amphibians and fish."
        ],
        "What are the ethical and logistical challenges associated with traditional nanobody development methods?": [
            "Immunizing camelids, which raises ethical concerns and logistical challenges.",
            "Using synthetic peptides, which are expensive and difficult to produce.",
            "Harvesting antibodies from human donors, which is invasive and time-consuming.",
            "Culturing bacteria to produce antibodies, which requires specialized equipment."
        ],
        "What technology does the synthetic phage-displayed nanobody library use to control amino acid composition in CDRs?": [
            "Trinucleotide-directed mutagenesis (TRIM) technology.",
            "Random mutagenesis technology.",
            "CRISPR-Cas9 gene editing technology.",
            "Site-directed mutagenesis technology."
        ],
        "Which specific viral protein is mentioned as a target for developing nanobodies against SARS-CoV-2?": [
            "The spike protein.",
            "The nucleocapsid protein.",
            "The envelope protein.",
            "The membrane protein."
        ],
        "Which targets were successfully isolated using the synthetic library, demonstrating its capability?": [
            "PD-1, ATXN1, and STAT3.",
            "CD4, CD8, and IL-6.",
            "EGFR, HER2, and VEGF.",
            "TNF-alpha, IL-1beta, and IFN-gamma."
        ]
    }
}